skip to main content
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Citeline
Search Icon Pharma Report StoreProduct loginProductLogin
Global Search Configuration

About Dean

UK

8+ years of experience

Dean_Rudge_Pharma_Intelligence
Joining the Generics bulletin team in 2013, Dean has five years of experience reporting on the global generic, biosimilar and value-added medicines industries.
Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.

Specialties

  • Biosimilars
  • Commercial Strategy
  • Market Access
  • Policy & Regulation
  • Pricing & Reimbursement

Dean writes For

Analyst Articles

Articles by Dean

  • Generics Bulletin

    Teva And Endo Overcome Opioid Claims In California

    By Dean Rudge 02 Nov 2021

    PS2107_opioidsstates_2C4EAH2_1200

    Following a recent settlement in Louisiana, Teva has been told by a court in California it is not liable for the state’s opioid crisis, avoiding for now the potential for significant damages.

    View article

  • Generics Bulletin

    Coronavirus Puts The Brakes On Mylan-Upjohn Merger

    By Dean Rudge 06 Apr 2020

    Coronavirus Puts The Brakes On Mylan-Upjohn Merger logo

    Mylan and Pfizer’s Upjohn were all set to merge into Viatris by midway through this year, subject to certain approvals, but that will now not happen in that timeframe as the global coronavirus pandemic proves an insurmountable barrier to getting the deal over the line.  

    Topic Coronavirus

    View article

  • Generics Bulletin

    Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

    By Dean Rudge 23 Mar 2020

    Donald Trump

    To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

    Topic Coronavirus

    View article

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy and Terms & Conditions for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device. Cookie Policy

I AGREE Cookies Settings